Drug Profile


Latest Information Update: 02 Dec 2004

Price : $50

At a glance

  • Originator Medical Discoveries
  • Class Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Clinical Phase Unknown HIV infections
  • Preclinical Asthma; Cystic fibrosis; Mycoses; Sepsis; Viral infections

Most Recent Events

  • 02 Dec 2004 Medical Discoveries has filed an IND with the FDA in the US for cystic fibrosis
  • 19 Aug 2004 Preclinical data from a media release have been added to the adverse events section
  • 12 Aug 2004 Preclinical data from a media release have been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top